Findings

What do systematic reviews say?

27 questions · 27 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 8 · 29.6%Very low 13 · 48.1%Low 4 · 14.8%Moderate 2 · 7.4%High 0 · 0%

Azoles vs placebo

Adverse effects Reported by investigators 'and' or 'or' participants · patients with tinea cruris and tinea corporis

It is very uncertain whether azoles changes adverse effects Reported by investigators 'and' or 'or' participants compared with placebo (very low certainty).

1 finding from 1 review

Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
RR 0.25 [0.06, 0.99]
3 studies · 266 participants
Very low

Azoles vs placebo

Relapse or recurrence Not assessed · patients with tinea cruris and tinea corporis

1 finding from 1 review

Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Azoles vs placebo

Participant‐judged cure Not assessed · patients with tinea cruris and tinea corporis

1 finding from 1 review

Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Azoles vs placebo

Duration of treatment until clinical cure Not assessed · patients with tinea cruris and tinea corporis

1 finding from 1 review

Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Azoles vs placebo

Episodes of confirmed vaginal candidiasis fungal smear · prevention and treatment of vulvovaginal candidiasis in women with HIV infection

It is very uncertain whether azoles changes episode of confirmed vaginal candidiasis Fungal Smears compared with placebo (very low certainty).

1 finding from 1 review

Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection 2011 · Cochrane Headline outcomes only
RR 0.63 [0.46, 0.88]
2 studies · 429 participants
Very low

Intervention not reported

In Vitro resistance to azoles ‐ Candida albicans MIC >= 64 micrograms/ml · prevention and treatment of vulvovaginal candidiasis in women with HIV infection

The intervention showed no clear difference in in Vitro resistance to azoles ‐ Candida albicans MIC >= 64… (moderate certainty).

1 finding from 1 review

Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection 2011 · Cochrane Headline outcomes only
RR 0.86 [0.15, 4.9]
1 study · 96 participants
Moderate

Intervention not reported

In Vitro resistance to azoles ‐ Non albicans Candida MIC>= 64 micrograms/ml · prevention and treatment of vulvovaginal candidiasis in women with HIV infection

The intervention probably leads to higher in Vitro resistance to azoles ‐ Non albicans Candida MIC>= 64… (moderate certainty).

1 finding from 1 review

Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection 2011 · Cochrane Headline outcomes only
RR 5.57 [1.7, 18.29]
1 study · 96 participants
Moderate